COMBINATION THERAPIES TARGETING TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND TOPOISOMERASE

The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a topoisomerase inhibitor; and (b) a therapeutically effe...

Full description

Saved in:
Bibliographic Details
Main Authors ZUDAIRE, ENRIQUE, ZHANG, XIAOYAN M, DIMITROV, DIMITER, SAHA, SAURABH, ST. CROIX, BRAD, ZHU, ZHONGYU
Format Patent
LanguageEnglish
French
Published 18.02.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a topoisomerase inhibitor; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody contains: (i) a heavy chain variable region (VH), which includes an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7; and (ii) a light chain variable region (VL), which includes an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8. Compositions, including pharmaceutical compositions, and kits for treating diseases, such as cancer, are also provided herein. La présente invention concerne, notamment, des méthodes de traitement ou d'amélioration des effets d'une maladie, telle qu'un cancer, chez un sujet. Lesdites méthodes comprennent l'administration, à un sujet en ayant besoin, (a) d'une quantité thérapeutiquement efficace d'un inhibiteur de la topoisomérase, et (b) d'une quantité thérapeutiquement efficace d'un anticorps monoclonal ou de son fragment de liaison à l'antigène, ledit anticorps monoclonal contenant : i) une région variable de chaîne lourde (VH), qui comprend une séquence d'acides aminés choisie parmi SEQ ID NO : 1, SEQ ID NO : 3, SEQ ID NO : 5, et SEQ ID NO : 7 ; et (ii) une région variable de chaîne légère (VL), qui comprend une séquence d'acides aminés choisie parmi SEQ ID NO : 2, SEQ ID NO : 4, SEQ ID NO : 6, et SEQ ID NO : 8. L'invention concerne également des compositions, notamment des compositions pharmaceutiques, et des kits pour le traitement de maladies, telles que le cancer.
Bibliography:Application Number: WO2015US34908